Day One Biopharmaceuticals joins ASCO26 to promote cancer care innovation

Day One Biopharmaceuticals joins ASCO26 to promote cancer care innovation
Day One at ASCO26

Day One Biopharmaceuticals is taking part in ASCO26, a leading annual gathering in the oncology community.

The company is engaging with attendees at booths 36155 and 12079 to share updates on its ongoing cancer research initiatives and efforts to improve oncology treatment. ASCO26 serves as a crucial platform for showcasing advancements and fostering collaboration within the field. Day One Biopharmaceuticals aims to connect with experts and reinforce its commitment to advancing new therapies for cancer patients.

Day One Biopharmaceuticals recently completed enrollment for its FIREFLY-2 trial, marking progress in pediatric glioma treatment efforts (story). The company is also set to present new data on its investigational therapy for adenoid cystic carcinoma at ASCO26 on June 1 (details). These milestones highlight the firm's ongoing clinical activity in oncology.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.